Journal article
Assessment of Response to Induction Therapy and Its Influence on 5-Year Failure-Free Survival in Group III Rhabdomyosarcoma: The Intergroup Rhabdomyosarcoma Study-IV Experience—A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group
Journal of clinical oncology, Vol.25(31), pp.4909-4913
11/01/2007
DOI: 10.1200/JCO.2006.10.4257
PMID: 17971587
Abstract
Purpose Initial response to induction chemotherapy predicts failure-free survival (FFS) in osteosarcoma and Ewing's sarcoma. For Intergroup Rhabdomyosarcoma Study (IRS) IV patients with group III rhabdomyosarcoma, we assessed whether reported response assessed by anatomic imaging at week 8 predicted FFS. Patients and Methods We studied 444 group III patients who received induction therapy, had response assessed at week 8 by anatomic imaging, and continued with protocol therapy. Induction chemotherapy was generally followed by radiation therapy (RT) starting after week 9. Response to induction therapy was determined at weeks 0 and 8. Local institutions coded response. Results Response rate for the entire cohort at week 8 was 77% (95% CI, 73% to 81%; complete response [CR], 21%; partial response [PR], 56%) but response had no influence on FFS (P = .57). Two hundred seventy-two patients received standard-timing RT at week 9 and thus only chemotherapy during induction. Response rate was 81% (95% CI, 76% to 86%; CR, 22%; PR, 59%). In these patients, response did not influence FFS except for those with alveolar histology. One hundred thirty-two other patients received chemotherapy and RT during induction (up-front RT). Response rate was 65% (95% CI, 57% to 73%; CR, 12%; PR, 53%), but response had no influence on FFS (P = .69). Forty patients received no RT at all (protocol violation) and response to induction therapy had no effect on FFS. Conclusion In IRS-IV, response rate to induction therapy was 77% in group III patients, was independent of histology, and had no influence on FFS overall.
Details
- Title: Subtitle
- Assessment of Response to Induction Therapy and Its Influence on 5-Year Failure-Free Survival in Group III Rhabdomyosarcoma: The Intergroup Rhabdomyosarcoma Study-IV Experience—A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group
- Creators
- Megan Burke - From the Children's Hospital Cleveland Clinic, Cleveland; Children's Hospital, Columbus, OH; University of Nebraska Medical Center, Omaha, NE; University of Iowa College of Medicine, Iowa City, IA; Children's Hospital, Pittsburgh, PA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Oklahoma Medical Science Center, Oklahoma City, OK; Duke University Medical Center; EMD Pharmaceuticals Inc, Durham, NC; and the Children's Oncology Group, Arcadia, CAJames R Anderson - From the Children's Hospital Cleveland Clinic, Cleveland; Children's Hospital, Columbus, OH; University of Nebraska Medical Center, Omaha, NE; University of Iowa College of Medicine, Iowa City, IA; Children's Hospital, Pittsburgh, PA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Oklahoma Medical Science Center, Oklahoma City, OK; Duke University Medical Center; EMD Pharmaceuticals Inc, Durham, NC; and the Children's Oncology Group, Arcadia, CASimon C Kao - From the Children's Hospital Cleveland Clinic, Cleveland; Children's Hospital, Columbus, OH; University of Nebraska Medical Center, Omaha, NE; University of Iowa College of Medicine, Iowa City, IA; Children's Hospital, Pittsburgh, PA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Oklahoma Medical Science Center, Oklahoma City, OK; Duke University Medical Center; EMD Pharmaceuticals Inc, Durham, NC; and the Children's Oncology Group, Arcadia, CADavid Rodeberg - From the Children's Hospital Cleveland Clinic, Cleveland; Children's Hospital, Columbus, OH; University of Nebraska Medical Center, Omaha, NE; University of Iowa College of Medicine, Iowa City, IA; Children's Hospital, Pittsburgh, PA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Oklahoma Medical Science Center, Oklahoma City, OK; Duke University Medical Center; EMD Pharmaceuticals Inc, Durham, NC; and the Children's Oncology Group, Arcadia, CAStephen J Qualman - From the Children's Hospital Cleveland Clinic, Cleveland; Children's Hospital, Columbus, OH; University of Nebraska Medical Center, Omaha, NE; University of Iowa College of Medicine, Iowa City, IA; Children's Hospital, Pittsburgh, PA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Oklahoma Medical Science Center, Oklahoma City, OK; Duke University Medical Center; EMD Pharmaceuticals Inc, Durham, NC; and the Children's Oncology Group, Arcadia, CASuzanne L Wolden - From the Children's Hospital Cleveland Clinic, Cleveland; Children's Hospital, Columbus, OH; University of Nebraska Medical Center, Omaha, NE; University of Iowa College of Medicine, Iowa City, IA; Children's Hospital, Pittsburgh, PA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Oklahoma Medical Science Center, Oklahoma City, OK; Duke University Medical Center; EMD Pharmaceuticals Inc, Durham, NC; and the Children's Oncology Group, Arcadia, CAWilliam H Meyer - From the Children's Hospital Cleveland Clinic, Cleveland; Children's Hospital, Columbus, OH; University of Nebraska Medical Center, Omaha, NE; University of Iowa College of Medicine, Iowa City, IA; Children's Hospital, Pittsburgh, PA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Oklahoma Medical Science Center, Oklahoma City, OK; Duke University Medical Center; EMD Pharmaceuticals Inc, Durham, NC; and the Children's Oncology Group, Arcadia, CAPhilip P Breitfeld - From the Children's Hospital Cleveland Clinic, Cleveland; Children's Hospital, Columbus, OH; University of Nebraska Medical Center, Omaha, NE; University of Iowa College of Medicine, Iowa City, IA; Children's Hospital, Pittsburgh, PA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Oklahoma Medical Science Center, Oklahoma City, OK; Duke University Medical Center; EMD Pharmaceuticals Inc, Durham, NC; and the Children's Oncology Group, Arcadia, CA
- Resource Type
- Journal article
- Publication Details
- Journal of clinical oncology, Vol.25(31), pp.4909-4913
- DOI
- 10.1200/JCO.2006.10.4257
- PMID
- 17971587
- NLM abbreviation
- J Clin Oncol
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 11/01/2007
- Academic Unit
- Radiology; Stead Family Department of Pediatrics
- Record Identifier
- 9984051707102771
Metrics
22 Record Views